UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 6, 2010, Pages 1423-1431

  Berg, Jeannette Zinggeler ^a   Von Weymarn, Linda B ^a   Thompson, Elizabeth A ^a   Wickham, Katherine M ^a   Weisensel, Natalie A ^a   Hatsukami, Dorothy K ^a   Murphy, Sharon E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYCOTININE; COTININE; GLUCURONIDE; NICOTINE; OXIDE; UDP GLUCURONSYLTRANSFERASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; GLUCURONOSYLTRANSFERASE; UGT2B10 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; GLUCURONIDATION; HETEROZYGOSITY; HUMAN; LIQUID CHROMATOGRAPHY; OXIDATION; PRIORITY JOURNAL; SMOKING; TANDEM MASS SPECTROMETRY; URINALYSIS; ADOLESCENT; AGED; BLOOD; FEMALE; GENETICS; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; OXYGEN CONSUMPTION; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHROMATOGRAPHY, LIQUID; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NICOTINE; OXYGEN CONSUMPTION; SMOKING; YOUNG ADULT;

EID: 77953319366     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0959     Document Type: Article

References (36)

1. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, v. 89. p. 553. Lyon (FR): IARC; 2007.
2. Hecht SS. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44.
3. Boffetta P, Clark S, Shen M, Gislefoss R, Peto R, Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:1184-8.
4. Vaccarella S, Herrero R, Snijders PJ, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37:536-46.
5. Nieters A, Rohrmann S, Becker N, et al. Smoking and lymphoma risk in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008;167:1081-9.
6. Murphy SE, Link CA, Jensen J, et al. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol Biomarkers Prev 2004;13:1617-23.
7. Benowitz NL. Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect 1999;107:349-55.
8. Scherer G, Engl J, Urban M, Gilch G, Janket D, Riedel K. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007;47:171-83.
9. Byrd GD, Robinson JH, Caldwell WS, deBethizy JD. Comparison of measured and FTC-predicted nicotine uptake in smokers. Psychopharmacology (Berl) 1995;122:95-103.
10. Etter JF, Perneger TV. Measurement of self reported active exposure to cigarette smoke. J Epidemiol Community Health 2001;55:674-80.
11. Strasser AA, Pickworth WB, Patterson F, Lerman C. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2004;13:1800-4.
12. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71.
13. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 2009;169:236-48.
14. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996;18:188-204. (Pubitemid 27082089)
15. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
16. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002;94:108-15.
17. Meger M, Meger-Kossien I, Schuler-Metz A, Janket D, Scherer G. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;778:251-61.
18. Benowitz NL, Jacob P III, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303. (Pubitemid 24039102)
19. Le Marchand L, Derby KS, Murphy SE, et al. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res 2008;68:9137-40.
20. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J 2007;7:81-98.
21. Benowitz NL, Swan GE, Jacob P III, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006;80:457-67.
22. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005;77:145-58.
23. Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000;64:383-90.
24. Kiyotani K, Yamazaki H, Fujieda M, et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 2003;13:689-95.
25. Haberl M, Anwald B, Klein K, et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 2005;15:609-24.
26. Derby KS, Cuthrell K, Caberto C, et al. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev 2008;17:3526-35.
27. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 codon 67 (Asp>Tyr) polymorphism. Cancer Res 2007;67:9024-9.
28. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M. Nicotine glucuronidation and the human UDP-glucuronosyl-transferase UGT2B10. Mol Pharmacol 2007;72:761-8.
29. Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 2008;18:181-91.
30. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 2004;39:970-7.
31. Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther 2010;332:202-9.
32. Hecht SS, Carmella SG, Chen M, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6.
33. Yamanaka H, Nakajima M, Nishimura K, et al. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 2004;22:419-25.
34. Kuehl GE, Murphy SE. N-Glucuronidation of nicotine and cotinine by human liver microsomes and heterologously-expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2003;31:1361-8.
35. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004;14:615-26.
36. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006;11:400-9.